Long-term study of zigakibart for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier zigakibart study for IgA nephropathy.
- You cannot be on long-term dialysis or have had a kidney transplant.
- You must not have had a serious kidney injury or very fast-worsening kidney disease in the last month.
- You cannot have taken strong immune-suppressing medicines or certain herbs for more than 2 weeks in the last 3 months.
- If you are able to become pregnant or father a child, you must use highly effective birth control during the study and for 24 weeks after your last dose.
- You must not have certain active infections like hepatitis or HIV, and no recent live vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
This trial studies the long-term effects of dazukibart in people who completed an earlier study for idiopathic inflammatory myopathies (a group of rare conditions causing muscle inflammation and weakness). It helps researchers understand how well the medicine works over a longer period.
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
This study tests a long-term treatment for people with IgA nephropathy, a kidney disease. It aims to see if continuing the treatment is safe and helpful over a longer period.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Hear when a new Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.